Integra LifeSciences beats, raises guidance as Essig returns as CEO

 

Integra LifeSciences beats Q1 2026 estimates, raises 2026 EPS guidance to $2.40–$2.50 as Essig returns as CEO

• Key results: Q1 2026 revenue $392m (+2.4% reported, +1.3% organic); EPS $0.54 vs $0.41, beating estimates.
• Guidance: 2026 revenue $1.66–$1.7bn unchanged; EPS raised to $2.40–$2.50 from $2.30–$2.40.
• Investor takeaway: Q1 beat on revenue and EPS plus Essig’s CEO return highlight renewed focus on execution.
• Leadership: Stuart Essig returns as CEO; prior CEO stepped down by mutual decision in leadership shift disclosed on Q1 call.
• Positive surprise: Tissue Reconstruction revenue grew +6.4% organic, driven by Integra Skin, DuraSorb, and PriMatrix products.
• Growth drivers: wound reconstruction sales +6.2%, neurosurgery +1.9% organic, capital CUSA double-digit, with CereLink performance strong.
• Problem areas: Specialty Surgery organic -0.6%; ENT, instruments, and international Tissue Reconstruction businesses declined.
• Margins: Q1 gross margin 64.1% and EBITDA margin 19.4%; 2026 gross margin guided to approximately 62.5%.
• Risk profile: ongoing quality remediation, delayed product relaunches, elevated leverage at 4.1x, and need for deleveraging amid modest organic growth.
• Notable items: tariff benefit contributed roughly $0.10 to EPS, Braintree facility starting in June, SurgiMend relaunch planned Q4.
• Q&A focus areas included Compliance Master Plan progress, wound-care reimbursement shifts, portfolio strategy, and PMA timing for SurgiMend and DuraSorb.
• Management highlighted a strong quarter driven by tissue reconstruction growth, margin expansion, and improving supply reliability across key franchises.

https://finviz.com/quote?t=IART&p=d